221 related articles for article (PubMed ID: 19298393)
1. The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus.
Radovits T; Bömicke T; Kökény G; Arif R; Loganathan S; Kécsán K; Korkmaz S; Barnucz E; Sandner P; Karck M; Szabó G
Br J Pharmacol; 2009 Mar; 156(6):909-19. PubMed ID: 19298393
[TBL] [Abstract][Full Text] [Related]
2. Vascular dysfunction induced by hypochlorite is improved by the selective phosphodiesterase-5-inhibitor vardenafil.
Radovits T; Arif R; Bömicke T; Korkmaz S; Barnucz E; Karck M; Merkely B; Szabó G
Eur J Pharmacol; 2013 Jun; 710(1-3):110-9. PubMed ID: 23623933
[TBL] [Abstract][Full Text] [Related]
3. Dose-dependent effects of a selective phosphodiesterase-5-inhibitor on endothelial dysfunction induced by peroxynitrite in rat aorta.
Korkmaz S; Radovits T; Barnucz E; Neugebauer P; Arif R; Hirschberg K; Loganathan S; Seidel B; Karck M; Szabó G
Eur J Pharmacol; 2009 Aug; 615(1-3):155-62. PubMed ID: 19482016
[TBL] [Abstract][Full Text] [Related]
4. Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3',5' guanosine monophosphate (cGMP) level in podocytes.
Fang L; Radovits T; Szabó G; Mózes MM; Rosivall L; Kökény G
Nephrol Dial Transplant; 2013 Jul; 28(7):1751-61. PubMed ID: 23203993
[TBL] [Abstract][Full Text] [Related]
5. Addition of vardenafil into storage solution protects the endothelium in a hypoxia-reoxygenation model.
Veres G; Hegedűs P; Barnucz E; Zöller R; Radovits T; Korkmaz S; Kolonics F; Weymann A; Karck M; Szabó G
Eur J Vasc Endovasc Surg; 2013 Aug; 46(2):242-8. PubMed ID: 23751217
[TBL] [Abstract][Full Text] [Related]
6. Vardenafil and resveratrol synergistically enhance the nitric oxide/cyclic guanosine monophosphate pathway in corpus cavernosal smooth muscle cells and its therapeutic potential for erectile dysfunction in the streptozotocin-induced diabetic rat: preliminary findings.
Fukuhara S; Tsujimura A; Okuda H; Yamamoto K; Takao T; Miyagawa Y; Nonomura N; Okuyama A
J Sex Med; 2011 Apr; 8(4):1061-71. PubMed ID: 21269399
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of myocardial and vascular function after phosphodiesterase-5 inhibition in a rat model.
Loganathan S; Radovits T; Korkmaz S; Hirschberg K; Barnucz E; Weymann A; Bömicke T; Arif R; Karck M; Szabó G
Thorac Cardiovasc Surg; 2012 Jun; 60(4):247-54. PubMed ID: 22252326
[TBL] [Abstract][Full Text] [Related]
8. Vardenafil protects against myocardial and endothelial injuries after cardiopulmonary bypass.
Szabó G; Radovits T; Veres G; Krieger N; Loganathan S; Sandner P; Karck M
Eur J Cardiothorac Surg; 2009 Oct; 36(4):657-64. PubMed ID: 19523842
[TBL] [Abstract][Full Text] [Related]
9. Targeting Phosphodiesterase-5 by Vardenafil Improves Vascular Graft Function.
Veres G; Hagenhoff M; Schmidt H; Radovits T; Loganathan S; Bai Y; Korkmaz-Icöz S; Brlecic P; Sayour AA; Karck M; Szabó G
Eur J Vasc Endovasc Surg; 2018 Aug; 56(2):256-263. PubMed ID: 29724533
[TBL] [Abstract][Full Text] [Related]
10. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
[TBL] [Abstract][Full Text] [Related]
11. Nitric oxide synthesis leads to vascular endothelial growth factor synthesis via the NO/cyclic guanosine 3',5'-monophosphate (cGMP) pathway in human corpus cavernosal smooth muscle cells.
Komori K; Tsujimura A; Takao T; Matsuoka Y; Miyagawa Y; Takada S; Nonomura N; Okuyama A
J Sex Med; 2008 Jul; 5(7):1623-35. PubMed ID: 18331270
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta.
Teixeira CE; Priviero FB; Webb RC
J Pharmacol Exp Ther; 2006 Feb; 316(2):654-61. PubMed ID: 16204472
[TBL] [Abstract][Full Text] [Related]
13. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats.
Morelli A; Filippi S; Sandner P; Fibbi B; Chavalmane AK; Silvestrini E; Sarchielli E; Vignozzi L; Gacci M; Carini M; Vannelli GB; Maggi M
J Sex Med; 2009 Jun; 6(6):1594-1608. PubMed ID: 19473460
[TBL] [Abstract][Full Text] [Related]
14. Vardenafil improves penile erection in type 2 diabetes mellitus patients with erectile dysfunction: role of tropomyosin.
Zamorano-León JJ; Olivier C; de Las Heras N; Mateos-Cáceres PJ; Brime Menéndez R; Rodríguez-Sierra P; Martín Palacios N; Manso LS; Modrego J; Segura A; Macaya C; López-Farré AJ
J Sex Med; 2013 Dec; 10(12):3110-20. PubMed ID: 24112450
[TBL] [Abstract][Full Text] [Related]
15. Modulation of vascular reactivity in normal, hypertensive and diabetic rat aortae by a non-antioxidant flavonoid.
Ajay M; Achike FI; Mustafa MR
Pharmacol Res; 2007 May; 55(5):385-91. PubMed ID: 17317209
[TBL] [Abstract][Full Text] [Related]
16. The effect of sildenafil on the altered thoracic aorta smooth muscle responses in rat pre-eclampsia model.
Turgut NH; Temiz TK; Bagcivan I; Turgut B; Gulturk S; Karadas B
Eur J Pharmacol; 2008 Jul; 589(1-3):180-7. PubMed ID: 18538317
[TBL] [Abstract][Full Text] [Related]
17. Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus.
Schäfer A; Fraccarollo D; Pförtsch S; Flierl U; Vogt C; Pfrang J; Kobsar A; Renné T; Eigenthaler M; Ertl G; Bauersachs J
Br J Pharmacol; 2008 Mar; 153(5):886-93. PubMed ID: 17891166
[TBL] [Abstract][Full Text] [Related]
18. Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes.
Mátyás C; Németh BT; Oláh A; Török M; Ruppert M; Kellermayer D; Barta BA; Szabó G; Kökény G; Horváth EM; Bódi B; Papp Z; Merkely B; Radovits T
Eur J Heart Fail; 2017 Mar; 19(3):326-336. PubMed ID: 27995696
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo effects of vardenafil (a PDE-5 Inhibitor) on corpus cavernosal smooth muscle relaxation in diabetic rabbits.
Lau DH; Mumtaz FH; Mikhailidis DP; Thompson CS
Urol Int; 2009; 82(1):101-7. PubMed ID: 19172107
[TBL] [Abstract][Full Text] [Related]
20. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil.
Saenz de Tejada I; Angulo J; Cuevas P; Fernández A; Moncada I; Allona A; Lledó E; Körschen HG; Niewöhner U; Haning H; Pages E; Bischoff E
Int J Impot Res; 2001 Oct; 13(5):282-90. PubMed ID: 11890515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
